on recombinant plasmid pEB1. Purification was accomplished by a series of column chromatography techniques: anion-exchange, chromatofocusing, cation-exchange, and monoclonal antibody affinity chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the pure toxin showed that SLT-II consisted of A and B subunits with apparent molecular weights of 32,000 and 10,200 + 800, respectively. A band of molecular weight 25,000 was also observed after sodium dodecyl sulfate-polyacrylamide gel electrophoresis and identified as the Al subunit by Western immunoblot analysis with toxin-specific monoclonal antibodies (MAbs). The pl of the purified toxin was 5. rabbit ileal segments, and paralytic-lethal for various laboratory animals (for a review, see reference 20). Based on nucleotide sequencing and predicted amino acid composition, SLT-I and Shiga toxin are identical or nearly identical proteins (4, 11, 31) . Although SLT-II and SLT-I are reported to have similar biological activities (33), SLT-II is not neutralized by anti-SLT-I or anti-Shiga toxin antibodies. Conversely, SLT-II neutralizing antibodies do not neutralize SLT-I or Shiga toxin.
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In addition to 0157:H7, E. coli strains of several other serotypes isolated from persons with HUS or hemorrhagic colitis produce either SLT-I or SLT-II or both (1, 15) . In the 10 outbreaks of hemorrhagic colitis and HUS investigated by the Centers for Disease Control to date, the presumptive epidemic strains have been serotype 0157:H7 and have produced SLT-II alone or SLT-I and SLT-II. Organisms received at the Centers for Disease Control that produce SLT-I alone have been recovered from sporadic cases of diarrhea, hemorrhagic colitis, or HUS. Although SLT-II was recognized later, the epidemiologic data suggest that SLT-II is at least as important as SLT-I as a potential virulence factor (30) . To facilitate the development of immunodiagnostic assays and to investigate the role of SLT-II in the pathogenesis of HUS and hemorrhagic colitis, we needed pure toxin. We report here the purification of SLT-II and the production of SLT-II-specific monoclonal antibodies (MAbs).
MATERIALS AND METHODS
Crude-toxin preparation. E. coli NM522(pEB1) (J. S. Spika, L. W. Mayer, and F. P. Downes, Abstr. Annu. Meet. Am. Soc. Microbiol. 1987, B-67, p. 36) was used as the source of toxin. E. coli NM522(pEB1) contains the cloned genes for SLT-II on the recombinant plasmid pEB1 (manu-SLT-II PURIFICATION AND MONOCLONAL ANTIBODY PRODUCTION script in preparation). Strain NM522(pEB1) was handled in accordance with the guidelines set forth by the Recombinant Advisory Committee (Appendix, Fed. Regist. 51: 16972, 1986 ). Since it produced less toxin than S. dysenteriae type 1 60R, all manipulation of strain NM522(pEB1) were performed under P2 containment.
Strain NM522(pEB1) was grown for 16 to 18 h at 37°C in Penassay broth (Difco Laboratories, Detroit, Mich.) supplemented with 35 ,ug of ampicillin per ml. Aliquots of the overnight growth were spread onto 65 (150 by 15 mm) Trypticase soy agar plates (BBL Microbiology Systems, Cockeysville, Md.), each containing 35 p,g of ampicillin per ml, and incubated overnight at 37°C. The bacterial growth was gently scraped from the plates at room temperature and washed twice by centrifugation at 4°C with 0.15 M NaCl. The bacteria were then suspended in 0.01 M N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) buffer (pH 7.2) and lysed by two passages in a French pressure cell (American Instruments, Urbana, Ill.) at 20,000 lb/i 2. Bacterial cells and the resulting lysate were kept on ice during the lysing procedure. To limit the viscosity of the preparation, RNase and DNase (Sigma Chemical Co., St. Louis, Mo.), each at 0.1 mg/ml, and 0.001 M MgCl2 were added to the lysate. The lysate was then centrifuged at 10,000 x g for 1 h at 4°C. Crude toxin was extracted from the resulting supernatant fluid by precipitation with 60% saturated ammonium sulfate at 4°C. The resulting precipitate was collected by centrifugation, redissolved in approximately 40 ml of distilled water (28) , and dialyzed three times at 4°C against 150 volumes of 0.1 M Tris hydrochloride (pH 6.5).
Anion-exchange chromatography. Manipulations of all chromatography columns were performed at room temperature. The dialyzed crude toxin was applied to a 50-ml (1.6 by 25 cm) DEAE-Sepharose CL-6B (Pharmacia, Uppsala, Sweden) column equilibrated with 0.1 M Tris hydrochloride (pH 6.5). The column was washed with the equilibration buffer until the optical density at 280 nm (OD280) of the eluate returned to base-line levels. The column was developed with 400 ml of a 0 to 0.6 M NaCl gradient in equilibration buffer, and the OD280 and cytotoxicity of 3-ml fractions were monitored. Fractions with greater than 104 50% cytotoxic doses/ml (CD5Jml) were pooled, concentrated to approximately 20 ml with a stirred-cell Amicon Concentrator (Amicon Corp., Danvers, Mass.) by using YM10 Diaflo Ultrafiltration Membrane Filters (Amicon Corp.), and dialyzed (Spectrapor, 6,000-to 8,000-molecular-weight cutoff; Spectrum Medical Industries, Inc., Los Angeles, Calif.) at 4°C against 300 volumes of 0.025 M histidine hydrochloride (pH 6.2).
Chromatofocusing chromatography. PBE 94 resin (Pharmacia) (21 ml) was equilibrated with 0.025 M histidine hydrochloride (pH 6.2) in a column (1.0 by 26 cm). The pooled, concentrated material from the anion-exchange column was applied to the chromatofocusing column, and Polybuffer 74 (Pharmacia), adjusted to pH 4.0 with 10 N HCI, was then applied to form a pH gradient between pH 6 and 4. The OD280 and cytotoxicity of 3-ml fractions were monitored, and fractions with greater than 104 CD50ml were pooled, concentrated as above, and dialyzed against 150 volumes of 0.2 M citrate buffer (pH 4.0).
Cation-exchange chromatography. The concentrated toxin preparation from the chromatofocusing column was applied to a 25-ml CM-Sepharose CL-6B (Pharmacia) column (1.0 by 30 cm) equilibrated with 0.2 M citrate buffer (pH 4.0). The column was washed with equilibration buffer until the OD280 of 3-ml fractions returned to base-line levels. Toxin was eluted with a salt gradient (400 ml of 0 to 0.6 M NaCl in equilibration buffer), and fractions with greater than 105 CD5J/ml were pooled and concentrated as above. and PBS (16) .
PAGE. In a determination of toxin purity and subunit structure, samples from individual chromatography fractions and concentrated pools were mixed with an equal volume of sample treatment buffer (0.125 M Tris hydrochloride [pH 6.8], 4% SDS, 20% glycerol, 10% 2-mercaptoethanol) and heated at 100°C for 4 to 10 min. The reduced and denatured samples were subjected to PAGE on 1.0-mm SDS-15% polyacrylamide gels as described by Laemmli (13) . After electrophoresis was complete, the gels were silver stairted to visualize the protein bands (17) . Unless otherwise specified, all gels were silver-stained to visualize the proteins. Concentrated toxin from the CM-Sepharose column was mixed at room temperature with sample treatment buffer without both 2-mercaptoethanol and SDS and electrophoresed under nondenaturing conditions on a 15% polyacrylamide gel. After electrophoresis, the gel was cut into 2-mm slices. The protein in each slice was passively eluted into PBS and assayed for cytotoxicity.
Protein determination. The protein content of the purification pools was monitored at the completion of each step of purification by using the Pierce BCA Protein Reagent or Pierce Coomassie Blue G-250 reagent (Pierce Chemical Co., Rockford, Ill.) (29) and bovine serum albumin as a standard.
HeLa cell cytotoxicity assays. Cytotoxicity was measured in 96-well HeLa cell microdilution cultures by the method of Gentry and Dalrymple (7). The toxin titer was defined as the reciprocal of the dilution that resulted in death of 50% of the HeLa cells (CD50). The neutralization assay was performed by mixing equal volumes of antiserum and toxin, both diluted in cell culture medium. The toxin-antitoxin mixture was incubated at 37°C for 1 to 4 h, and 0.1 ml of the mixture was assayed on HeLa cells for residual cytotoxicity as previously described (7) Preparation of rabbit antisera. Polyclonal rabbit antisera were prepared against SLT-I purified from E. coli 0157:H7 strain 931 as described by O'Brien and LaVeck (22) and against partially purified SLT-II (CM-Sepharose fraction) from E. coli NM522(pEB1). Toxoids were prepared from the purified toxins by treatment with glutaraldehyde as described by Brown et al. (2) , and portions (20 5, 7 , and 9 days after the booster injection, and the serum samples from a given rabbit were pooled.
Isoelectric-point determination. The pl of affinity-purified toxin was determined by using thin-layer electrofocusing acrylamide gels (PAG-plate; LKB Instruments, Inc., Rockville, Md.). An anode buffer of 1 M phosphoric acid and a cathode buffer of 1 M sodium hydroxide were used for a pH range of 3.5 to 9.5. Gels were electrophoresed for 90 min at 50 mA. Iso-gel pl Markers (FMC Corp., Marine Colloids Div., Rockland, Maine) were used as standards.
RESULTS
Toxin purification. As a source of toxin we used an E. coli K-12 strain transformed with the recombinant plasmid pEB1 carrying the SLT-II genes from E. coli EDL880 (serotype 0157:H7), which produces both SLT-I and SLT-II. We chose the transformed strain to avoid contamination of our toxin preparation with SLT-I and because it produced 100-fold more SLT-II than the wild-type parent did.
As an initial purification step, the bacterial cell lysate was precipitated with 60% saturated ammonium sulfate. The precipitated crude toxin was then subjected to anion-exchange (Fig. 1), chromatofocusing (Fig. 2) , cation-exchange (Fig. 3) , and monoclonal anti-toxin affinity chromatography. Using this scheme, we obtained highly purified toxin with a specific activity of 9.1 x 108 CD5Jmg (Table 1) .
In initial attempts to purify the toxin, molecular sieve chromatography with Bio-Gel P-100 resin (Bio-Rad Laboratories) was introduced after chromatofocusing chromatography. This technique did not increase the purity or yield of toxin and was omitted in subsequent experiments. In contrast, cation-exchange chromatography proved to be a very efficient method of purification. Initial attempts to simplify the procedure by omitting the DEAE and chromatofocusing chromatography steps were unsuccessful. Crude toxin precipitated by ammonium sulfate did not bind efficiently to the CM-Sepharose column. It is possible that contaminants which would have been removed by the DEAE and chromatofocusing columns interfered with the binding of the toxin to the cation-exchange column.
After CM-Sepharose chromatography, the toxin had been purified over 3,000-fold. Nondenaturing PAGE of the toxin preparation after this step revealed only one major protein band that coincided with the peak of cytotoxic activity eluted from the gel (Fig. 4) . The two lightly staining bands near the cathode were attributed to contaminants in the Tris buffers, since they appeared in lanes without samples as well as in lanes containing samples. In later gels (Fig. 5) , the bands disappeared when a new lot of Tris base was used for the preparation of the gels.
The immunoaffinity column was made with MAb BC5 BB12, which recognized the B subunit of SLT-II (see Fig. 7 ). The affinity column step resulted in approximately a 12% increase in specific activity (Table 1) affinity column could conceivably have been a mixture of holotoxin and free B subunits, the pure toxin was subjected to gel filtration chromatography on Bio-Gel P-100 resin. Fractions were monitored for cytotoxic activity and the presence of B subunit by SDS-PAGE. No fractions containing only B subunit were detected (data not shown).
Characterization of SLT-II. When applied to SDS-PAGE, affinity-purified toxin separated into three bands (Fig. 5 ). Shiga toxin (20) . Western blot analysis showed that the A and the putative A1 subunits were both recognized by SLT-II specific MAbs DC1 EH5 and GB6 BA4 (see Fig. 7 ).
Isoelectric focusing gels of affinity-purified SLT-II have shown one or two bands in the pH range of 5.1 to 5.3. Isoelectric focusing of the affinity-purified toxin in thin-layer polyacrylamide gels showed a sharp, intensely staining band with a PI of 5.2 and fainter bands with pls around 5.1 (Fig.  6 ). In some purified toxin preparations after electrofocusing on agarose gels, we observed two sharp bands with pIs of 5.2 and 5.3. Cytotoxicity assays on material eluted from slices of the agarose gel revealed that virtually all the cytotoxic activity applied to the gel migrated in the same location as the protein bands at pH 5.2 and 5.3 (data not shown). The two bands may represent holotoxin and free B subunit, which has a predicted pI of 5.38 (10) (processed B subunit). Alternatively, the two bands may represent heterogeneity in the holotoxin owing to various numbers of B subunits associated with the A subunit. Heterogeneity in the holotoxin is more likely, since no free B subunit was detected in that affinity-purified toxin preparation by gel filtration.
The pure toxin was cytotoxic to HeLa cells and Vero cell monolayers (see Table 3 ). As little as 1.1 pg of pure toxin killed 50% of the HeLa cells in the microdilution cytotoxicity assay (Table 1) . SLT-II-specific polyclonal antibodies and MAbs neutralized the pure toxin, whereas anti-SLT-I MAb 13C4 did not neutralize the toxin (Table 2) . Preliminary experiments with purified SLT-II showed that the toxin was lethal for mice and rabbits (data not shown).
MAb production. The use of a toxoid of partially purified toxin as the antigen facilitated the production of five hybridoma cell lines which produced SLT-II neutralizing antibodies ( Table 2 ). All monoclones characterized were of the IgGl heavy-chain and kappa light-chain classes.
Two monoclones recognized the A and A1 subunits of Western-blotted toxin proteins, whereas the remaining three monoclones recognized the B subunit ( Fig. 7; Table 3 ). None of the five SLT-II-specific antibodies described here bound to the A or B subunits of Western-blotted crude Shiga toxin. MAb 13C4 did not bind to the subunits of SLT-II; however, it did recognize the B subunit of Western-blotted crude Shiga toxin (data not shown). The A and B subunits of SLT-II have molecular weights of 32,000 and 10,200 ± 800, respectively, whereas the A and B subunits of VT2 have molecular weights of 35,000 and 10,700, respectively. The sizes of the subunits for SLT-II are also consistent with minicell and DNA sequence data reported for SLT-II (10, 18) . From the DNA sequence analysis of SLT-II, the predicted molecular weights of the mature A and B subunits were 33,135 and 7,817.
DISCUSSION
The observed sizes of the B subunits for SLT-II and VT2
were larger than predicted for the mature B subunit from the nucleotide sequence data. The degree to which the B subunit is processed for SLT-II or VT2 is not known. Newland et al. (18) observed no processing of the SLT-II A and B subunits with polymyxin B treatment of labeled minicells. In contrast, Padhye et al. (26) report that their toxin does not consist of subunits. The molecular weight of their toxin is 64,000 by SDS-PAGE and 54,000 by molecular-sieve chromatography. Although single bands are evident after Coomassie blue staining of SDS-polyacrylamide and isoelectric focusing gels, it is not clear from their data that the cytotoxicity migrated with these protein bands.
SLT-II purified in our study had a pI of 5. toxins from different strains. Heterogeneity in the number of B subunits associated with the A subunit may also account for the broad pH range over which SLT-II eluted from the chromatofocusing column. The pIs of SLT-II and VT2 may also differ with the source of the toxins (cell associated versus extracellular) used in the purification schemes. It is interesting that the toxin of Padhye et al. has the same pI as SLT-II but does not consist of A and B subunits. In contrast, the pIs of Shiga toxin and SLT-I (7.03 + 0.02 [22] ) are quite different from those of SLT-II, VT2, and the unique Vero cytotoxin.
The biologic activities of SLT-II and the toxins purified by Yutsudo et al. (35) and Padhye et al. (26) were similar; however, the specific activities differed. All three toxins were cytotoxic to either Vero or HeLa cells and lethal for mice. For both SLT-II and VT2, 1 CD50 unit was approximately 1 pg; however, for the toxin purified by Padhye et al., 1 CD50 unit was 25 pg. There was over a 200-fold difference between the 50% lethal doses of VT2 and the unique Vero cytotoxin for mice. Yutsudo et al. report that 1 ng of VT2 was a 50% lethal dose (20-g ddY mice, intraperitoneal injection), whereas Padhye et al. report that 270 ng of unique Vero cytotoxin was a 50% mouse lethal dose (20-g SpragueDawley mice, intraperitoneal injection) (25) . Variation in specific activities could result from differing amounts of inactive toxin such as free B or A subunits, varying degrees of purity, or differing sensitivities of the cell lines or animals.
No cross-neutralization was apparent in reciprocal titrations of Shiga toxin and SLT-II against specific polyclonal antibodies and MAbs. On the basis of biochemical characteristics such as pI and immunological characteristics in neutralization experiments, Shiga toxin or SLT-I and SLT-II were dissimilar. However, biologic similarities between these toxins may be more important in determining their relevance in the pathogenicity of a newly recognized group of enterohemorrhagic E. coli strains (14) .
The identification of SLT-producing bacteria by the cell culture toxicity assay is time-consuming and expensive, and requires a level of expertise and special facilities not generally available in clinical or public health microbiology laboratories. The development of rapid, simple assays for these toxins should facilitate more widespread testing for these organisms and subsequently lead to a better appreciation of their prevalence. The purification of SLT-II and the production of specific MAbs have provided reagents for the development of assays to detect this toxin and antibodies against it in specimens from patients. Using these reagents, we have developed an enzyme-linked immunosorbent assay for SLT-II (F. P. Downes et al., manuscript in preparation). The purified toxins and monoclones should also facilitate animal studies of hemorrhagic colitis and HUS and help define the role of SLTs in these diseases. 
